• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CRISPR-Cas核酸酶的协同工程实现了强大的哺乳动物基因组编辑。

Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editing.

作者信息

Chen Yangcan, Hu Yanping, Wang Xinge, Luo Shengqiu, Yang Ning, Chen Yi, Li Zhikun, Zhou Qi, Li Wei

机构信息

State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.

University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

Innovation (Camb). 2022 May 26;3(4):100264. doi: 10.1016/j.xinn.2022.100264. eCollection 2022 Jul 12.

DOI:10.1016/j.xinn.2022.100264
PMID:35693153
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9184807/
Abstract

The naturally occurring prokaryotic CRISPR-Cas systems provide valuable resources for the development of new genome-editing tools. However, the majority of prokaryotic Cas nucleases exhibit poor editing efficiency in mammalian cells, which significantly limits their utility. Here, we have developed a method termed Improving Editing Activity by Synergistic Engineering (MIDAS). This method exerts a synergistic effect to improve mammalian genome-editing efficiency of a wide range of CRISPR-Cas systems by enhancing the interactions between Cas nuclease with the protospacer adjacent motif (PAM) and the single-stranded DNA (ssDNA) substrate in the catalytic pocket simultaneously. MIDAS robustly and significantly increased the gene-editing efficiency of Cas12i, Cas12b, and CasX in human cells. Notably, a Cas12i variant, Cas12i , exhibited robust activity with a very broad PAM range (NTNN, NNTN, NAAN, and NCAN) and higher efficiency than the current widely used Cas nucleases. A high-fidelity version of Cas12i (Cas12i ) has been further engineered to minimize off-target effects. Our work provides an expandable and efficacious method for engineering Cas nucleases for robust mammalian genome editing.

摘要

天然存在的原核生物CRISPR-Cas系统为开发新的基因组编辑工具提供了宝贵资源。然而,大多数原核生物Cas核酸酶在哺乳动物细胞中的编辑效率较低,这显著限制了它们的实用性。在此,我们开发了一种名为“通过协同工程提高编辑活性”(MIDAS)的方法。该方法通过同时增强Cas核酸酶与原间隔序列相邻基序(PAM)以及催化口袋中单链DNA(ssDNA)底物之间的相互作用,发挥协同效应来提高多种CRISPR-Cas系统在哺乳动物中的基因组编辑效率。MIDAS显著且有力地提高了人细胞中Cas12i、Cas12b和CasX的基因编辑效率。值得注意的是,一种Cas12i变体Cas12i 具有很强的活性,其PAM范围非常广泛(NTNN、NNTN、NAAN和NCAN),且效率高于目前广泛使用的Cas核酸酶。我们进一步构建了高保真版本的Cas12i (Cas12i )以尽量减少脱靶效应。我们的工作为构建用于高效哺乳动物基因组编辑的Cas核酸酶提供了一种可扩展且有效的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/26a53a2ee4b8/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/2356496fe724/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/2ab11501b9c4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/f3f50fbb304e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/b305a418f7a9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/838c62465f2d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/02d76333e2ed/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/26a53a2ee4b8/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/2356496fe724/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/2ab11501b9c4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/f3f50fbb304e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/b305a418f7a9/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/838c62465f2d/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/02d76333e2ed/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5d8/9184807/26a53a2ee4b8/gr6.jpg

相似文献

1
Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editing.CRISPR-Cas核酸酶的协同工程实现了强大的哺乳动物基因组编辑。
Innovation (Camb). 2022 May 26;3(4):100264. doi: 10.1016/j.xinn.2022.100264. eCollection 2022 Jul 12.
2
An engineered Cas12i nuclease that is an efficient genome editing tool in animals and plants.一种经过工程改造的Cas12i核酸酶,它是一种在动物和植物中高效的基因组编辑工具。
Innovation (Camb). 2024 Jan 8;5(2):100564. doi: 10.1016/j.xinn.2024.100564. eCollection 2024 Mar 4.
3
Improve meat production and virus resistance by simultaneously editing multiple genes in livestock using Cas12i.利用 Cas12i 同时编辑家畜中的多个基因以提高肉质产量和抗病毒能力。
Sci China Life Sci. 2024 Mar;67(3):555-564. doi: 10.1007/s11427-023-2407-0. Epub 2023 Nov 17.
4
Exploiting endogenous CRISPR-Cas system for multiplex genome editing in Clostridium tyrobutyricum and engineer the strain for high-level butanol production.利用内源性 CRISPR-Cas 系统对酪丁酸梭菌进行多重基因组编辑,并对该菌株进行工程改造以提高丁醇产量。
Metab Eng. 2018 May;47:49-59. doi: 10.1016/j.ymben.2018.03.007. Epub 2018 Mar 9.
5
CRISPR/Cas genome editing to optimize pharmacologically active plant natural products.CRISPR/Cas 基因组编辑优化具有药理活性的植物天然产物。
Pharmacol Res. 2021 Feb;164:105359. doi: 10.1016/j.phrs.2020.105359. Epub 2020 Dec 4.
6
Repurposing CRISPR-Cas12b for mammalian genome engineering.将CRISPR-Cas12b重新用于哺乳动物基因组工程。
Cell Discov. 2018 Nov 27;4:63. doi: 10.1038/s41421-018-0069-3. eCollection 2018.
7
Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing.工程化 Cas12i2 是一种多功能、高效的治疗性基因组编辑平台。
Nat Commun. 2022 May 20;13(1):2833. doi: 10.1038/s41467-022-30465-7.
8
PAM-free diagnostics with diverse type V CRISPR-Cas systems.采用多种V型CRISPR-Cas系统的无PAM诊断方法。
medRxiv. 2024 May 3:2024.05.02.24306194. doi: 10.1101/2024.05.02.24306194.
9
Cas12n nucleases, early evolutionary intermediates of type V CRISPR, comprise a distinct family of miniature genome editors.Cas12n 核酸酶是 V 型 CRISPR 的早期进化中间体,属于一类独特的微型基因组编辑酶家族。
Mol Cell. 2023 Aug 3;83(15):2768-2780.e6. doi: 10.1016/j.molcel.2023.06.014. Epub 2023 Jul 3.
10
Expanding the plant genome editing toolbox with recently developed CRISPR-Cas systems.利用最近开发的 CRISPR-Cas 系统扩展植物基因组编辑工具包。
Plant Physiol. 2022 Mar 28;188(4):1825-1837. doi: 10.1093/plphys/kiac027.

引用本文的文献

1
An engineered CRISPR-Cas12i tool for efficient multiplexed genome editing.一种用于高效多重基因组编辑的工程化CRISPR-Cas12i工具。
Nucleic Acids Res. 2025 Aug 27;53(16). doi: 10.1093/nar/gkaf806.
2
ENHANCED CLEAVAGE OF GENOMIC USING CASX2.使用CasX2增强基因组切割
bioRxiv. 2025 Jul 11:2025.07.08.663680. doi: 10.1101/2025.07.08.663680.
3
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies.源自多能干细胞的工程化CRO-CD7嵌合抗原受体自然杀伤细胞可避免自相残杀,并有效抑制人类T细胞恶性肿瘤。

本文引用的文献

1
Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing.用于哺乳动物基因组调控与编辑的工程化微型CRISPR-Cas系统。
Mol Cell. 2021 Oct 21;81(20):4333-4345.e4. doi: 10.1016/j.molcel.2021.08.008. Epub 2021 Sep 3.
2
Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus.腺相关病毒递送超紧凑型 Cas12f1 和工程化向导 RNA 实现高效 CRISPR 编辑。
Nat Biotechnol. 2022 Jan;40(1):94-102. doi: 10.1038/s41587-021-01009-z. Epub 2021 Sep 2.
3
Inhibition of CRISPR-Cas12a DNA targeting by nucleosomes and chromatin.
J Hematol Oncol. 2025 May 19;18(1):57. doi: 10.1186/s13045-025-01712-3.
4
CRISPR-Cas12i confers efficient genome editing and gene regulation in plants.CRISPR-Cas12i在植物中赋予高效的基因组编辑和基因调控能力。
Plant Physiol. 2025 Apr 30;198(1). doi: 10.1093/plphys/kiaf125.
5
Mitochondrial DNA editing: Key to the treatment of neurodegenerative diseases.线粒体DNA编辑:治疗神经退行性疾病的关键。
Genes Dis. 2024 Sep 21;12(4):101437. doi: 10.1016/j.gendis.2024.101437. eCollection 2025 Jul.
6
Genome Editing in Mouse Embryo Using the CRISPR/Cas12i3 System.使用CRISPR/Cas12i3系统对小鼠胚胎进行基因组编辑
Int J Mol Sci. 2025 Mar 26;26(7):3036. doi: 10.3390/ijms26073036.
7
Single-cut gene therapy in a one-step generated rhesus monkey model of Duchenne muscular dystrophy.在一步法生成的杜氏肌营养不良恒河猴模型中的单切口基因治疗。
Cell Rep Med. 2025 Apr 15;6(4):102037. doi: 10.1016/j.xcrm.2025.102037. Epub 2025 Mar 26.
8
Latent activity in TnpB revealed by mutational scanning.通过突变扫描揭示的TnpB潜在活性
bioRxiv. 2025 Feb 16:2025.02.11.637750. doi: 10.1101/2025.02.11.637750.
9
Mitochondrial diseases: from molecular mechanisms to therapeutic advances.线粒体疾病:从分子机制到治疗进展
Signal Transduct Target Ther. 2025 Jan 10;10(1):9. doi: 10.1038/s41392-024-02044-3.
10
Protocol for evaluating the activity of R2 retrotransposons in mammalian cells.评估R2反转录转座子在哺乳动物细胞中活性的实验方案。
STAR Protoc. 2025 Mar 21;6(1):103538. doi: 10.1016/j.xpro.2024.103538. Epub 2025 Jan 6.
核小体和染色质对 CRISPR-Cas12a DNA 靶向的抑制作用。
Sci Adv. 2021 Mar 10;7(11). doi: 10.1126/sciadv.abd6030. Print 2021 Mar.
4
Structure of the miniature type V-F CRISPR-Cas effector enzyme.微型 V-F CRISPR-Cas 效应酶的结构。
Mol Cell. 2021 Feb 4;81(3):558-570.e3. doi: 10.1016/j.molcel.2020.11.035. Epub 2020 Dec 16.
5
Structural basis for two metal-ion catalysis of DNA cleavage by Cas12i2.Cas12i2 通过两个金属离子催化 DNA 切割的结构基础。
Nat Commun. 2020 Oct 16;11(1):5241. doi: 10.1038/s41467-020-19072-6.
6
Mechanisms for target recognition and cleavage by the Cas12i RNA-guided endonuclease.Cas12i RNA 引导内切酶的靶标识别和切割机制。
Nat Struct Mol Biol. 2020 Nov;27(11):1069-1076. doi: 10.1038/s41594-020-0499-0. Epub 2020 Sep 7.
7
CRISPR-CasΦ from huge phages is a hypercompact genome editor.来自巨型噬菌体的 CRISPR-CasΦ 是一种超紧凑型基因组编辑工具。
Science. 2020 Jul 17;369(6501):333-337. doi: 10.1126/science.abb1400.
8
CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity.CHANGE-seq 揭示了遗传和表观遗传对 CRISPR-Cas9 全基因组活性的影响。
Nat Biotechnol. 2020 Nov;38(11):1317-1327. doi: 10.1038/s41587-020-0555-7. Epub 2020 Jun 15.
9
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.无约束基因组靶向的近无 PAM 工程化 CRISPR-Cas9 变体。
Science. 2020 Apr 17;368(6488):290-296. doi: 10.1126/science.aba8853. Epub 2020 Mar 26.
10
Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants.CRISPR-Cas 系统的进化分类:Class 2 及其衍生变体的爆发。
Nat Rev Microbiol. 2020 Feb;18(2):67-83. doi: 10.1038/s41579-019-0299-x. Epub 2019 Dec 19.